- Home
- INTS vs BTBD Comparison
INTS vs BTBD Comparison
Compare INTS & BTBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- BTBD
- Stock Information
- Founded
- INTS 2012
- BTBD 1987
- Country
- INTS United States
- BTBD United States
- Employees
- INTS N/A
- BTBD N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- BTBD Restaurants
- Sector
- INTS Health Care
- BTBD Consumer Discretionary
- Exchange
- INTS Nasdaq
- BTBD Nasdaq
- Market Cap
- INTS 8.4M
- BTBD 9.1M
- IPO Year
- INTS 2023
- BTBD 2021
- Fundamental
- Price
- INTS $0.30
- BTBD $1.76
- Analyst Decision
- INTS Strong Buy
- BTBD
- Analyst Count
- INTS 4
- BTBD 0
- Target Price
- INTS $4.50
- BTBD N/A
- AVG Volume (30 Days)
- INTS 5.8M
- BTBD 6.6M
- Earning Date
- INTS 08-07-2025
- BTBD 08-19-2025
- Dividend Yield
- INTS N/A
- BTBD N/A
- EPS Growth
- INTS N/A
- BTBD N/A
- EPS
- INTS N/A
- BTBD N/A
- Revenue
- INTS N/A
- BTBD $14,533,449.00
- Revenue This Year
- INTS N/A
- BTBD N/A
- Revenue Next Year
- INTS N/A
- BTBD N/A
- P/E Ratio
- INTS N/A
- BTBD N/A
- Revenue Growth
- INTS N/A
- BTBD 1.58
- 52 Week Low
- INTS $0.19
- BTBD $1.00
- 52 Week High
- INTS $4.35
- BTBD $5.60
- Technical
- Relative Strength Index (RSI)
- INTS 49.95
- BTBD 53.94
- Support Level
- INTS $0.28
- BTBD $1.50
- Resistance Level
- INTS $0.32
- BTBD $1.72
- Average True Range (ATR)
- INTS 0.03
- BTBD 0.23
- MACD
- INTS 0.01
- BTBD -0.04
- Stochastic Oscillator
- INTS 78.80
- BTBD 22.22
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.